Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.79 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.79 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.79 |
| ▸ | MAOA | P21397 | 1/20 | 0.79 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.79 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.79 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.79 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.79 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amphetamine SCHEMBL29102142 | 1.00 | TAAR1 (0.79) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL29102157 | 0.92 | TAAR1 (0.79) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL27293366 | 0.92 | TAAR1 (0.79) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL8589685 | 0.92 | TAAR1 (0.79) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL3513103 | 0.90 | TAAR1 (0.70) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL29127738 | 0.90 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL28990193 | 0.89 | TAAR1 (0.91) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Levamfetamine SCHEMBL9673275 | 0.89 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL13747801 | 0.89 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL1560962 | 0.89 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320178-A1 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | NOVEN PHARMACEUTICALS, INC. (US) | 2025-10-16 | — | — | US | claimed |
| US-12427122-B2 | Method of making transdermal amphetamine composition with low levels of carbamate | NOVEN PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | claimed |
| US-20240327337-A1 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | NOVEN PHARMACEUTICALS, INC. (US) | 2024-10-03 | — | — | US | claimed |
| CN-117529665-A | Amphetamine carbamate compounds and methods | 诺芬药品公司 | 2024-02-06 | — | — | CN | claimed |
| EP-4274555-A1 | TRANSDERMAL AMPHETAMINE COMPOSITIONS WITH LOW LEVELS OF CARBAMATE | NOVEN PHARMACEUTICALS, INC. (US) | 2023-11-15 | — | — | EP | claimed |
| EP-4275055-A2 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | NOVEN PHARMACEUTICALS, INC. (US) | 2023-11-15 | — | — | EP | claimed |
| CN-116997330-A | Transdermal amphetamine compositions with low levels of carbamate | 诺芬药品公司 | 2023-11-03 | — | — | CN | claimed |
| US-20230201139-A1 | TRANSDERMAL AMPHETAMINE COMPOSITIONS WITH LOW LEVELS OF CARBAMATE | NOVEN PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | claimed |
| US-11572339-B2 | Amphetamine carbamate compounds and methods | NOVEN PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | claimed |
| US-20220218628-A1 | TRANSDERMAL AMPHETAMINE COMPOSITIONS WITH LOW LEVELS OF CARBAMATE | NOVEN PHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | US | claimed |
| WO-2022150430-A1 | TRANSDERMAL AMPHETAMINE COMPOSITIONS WITH LOW LEVELS OF CARBAMATE | NOVEN PHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022150431-A2 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | NOVEN PHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| US-20220213029-A1 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | NOVEN PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | US | claimed |
| US-20260102362-A1 | TRANSDERMAL AMPHETAMINE COMPOSITIONS WITH LOW LEVELS OF CARBAMATE | NOVEN PHARMACEUTICALS, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260102362-A1 | TRANSDERMAL AMPHETAMINE COMPOSITIONS WITH LOW LEVELS OF CARBAMATE | NOVEN PHARMACEUTICALS, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250320178-A1 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | NOVEN PHARMACEUTICALS, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2012031125-A2 | REVERSAL OF GENERAL ANESTHESIA BY ADMINISTRATION OF METHYLPHENIDATE, AMPHETAMINE, MODAFINIL, AMANTADINE, AND/OR CAFFEINE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20110021564-A1 | METHOD OF TREATING BINGE EATING DISORDER AND OBESITY RESULTING FROM BINGE EATING BEHAVIOR | LCS GROUP, LLC (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100166889-A1 | METHOD OF TREATING DEPRESSIVE DISORDERS | LCS GROUP, LLC (US) | 2010-07-01 | — | — | US | disclosed |
| WO-2009035473-A2 | METHOD OF TREATING BINGE EATING DISORDER, OBESITY RESULTING FROM BINGE EATING BEHAVIOR AND DEPRESSIVE DISORDERS | SANFILIPPO LOUIS C (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327337-A1 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | CHAT, CES2, NAAA | SLC6A2 98/4885SLC6A3 14/4885TAAR1 97/4885 |
| US-20260102362-A1 | TRANSDERMAL AMPHETAMINE COMPOSITIONS WITH LOW LEVELS OF CARBAMATE | SLC6A2, SLC6A3, CHAT | SLC6A2 1/4885SLC6A3 2/4885TAAR1 72/4885 |
| US-20220213029-A1 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | CHAT, CES2, NAAA | SLC6A2 98/4885SLC6A3 14/4885TAAR1 97/4885 |
| US-20110021564-A1 | METHOD OF TREATING BINGE EATING DISORDER AND OBESITY RESULTING FROM BINGE EATING BEHAVIOR | COMT, MC4R, SLC6A4 | SLC6A2 38/4885SLC6A3 6/4885TAAR1 229/4885 |
| US-20100166889-A1 | METHOD OF TREATING DEPRESSIVE DISORDERS | HTR5A, SLC6A4, HTR4 | SLC6A2 7/4885SLC6A3 12/4885TAAR1 107/4885 |
| US-11572339-B2 | Amphetamine carbamate compounds and methods | CHAT, CES2, NAAA | SLC6A2 98/4885SLC6A3 14/4885TAAR1 97/4885 |
| US-20250320178-A1 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | CHAT, CES2, NAAA | SLC6A2 98/4885SLC6A3 14/4885TAAR1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.